---
title: "Lysergide (DT120) in Generalized anxiety disorder: Conclusions"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Conclusions. 1 evidence topic quoted from 19 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary/conclusions"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Conclusions

<a id="heading-1.1.4"></a>

## 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

### Summary

- Burden and current therapy: past-year GAD prevalence among U.S. adults aged 18 to 65 was 10.0% (95% CI 8.3% to 12.1%). Up to 50% of patients respond inadequately to available agents, SSRI and SNRI discontinuation rates are 20% to 23%, and benzodiazepines carry a class boxed warning.
- Efficacy: in the phase 3 trials Voyage (214 participants) and Panorama (245 participants), a single dose of DT120 ODT 100 µg reduced the Week 12 HAM-A total score by 5.4 and 5.1 points more than placebo (both p<0.0001). These are company topline disclosures; one author states that adoption will depend on full peer-reviewed reporting. The published phase 2b trial (198 participants, capsules) reported a Week 4 difference of -5.0 points (95% CI, -9.6 to -0.4) with 100 µg.
- Safety: with 100 µg versus placebo, TEAEs occurred in 99% versus 69% of participants in Voyage and 94.8% versus 62.9% in Panorama, predominantly on the dosing day. As of September 14, 2026, 14 participants across all DT120 studies had a treatment-emergent serious adverse event, 1 deemed treatment-related.
- Regulatory status: not approved; Breakthrough Therapy designation for GAD (March 2024); NDA filing anticipated in the first half of 2027.
- Monitoring and scheduling: the pivotal trials required 8 hours of monitoring and an end-of-session checklist, which the sponsor intends to inform a potential REMS. Lysergide is Schedule I and must be rescheduled by the DEA and states after approval.
- Economics: price not established; the sponsor stated a corridor of $30,000 to $75,000 per treatment course. The report holds no cost-effectiveness or budget impact model of DT120, only ICER evaluations of esketamine and MDMA-assisted psychotherapy.
- Evidence gaps: peer-reviewed phase 3 reports; functional unblinding (91% and 95% of Panorama participants given 50 µg and 100 µg guessed assignment to drug); active comparators; durability and retreatment beyond 12 weeks (Part B data are open-label and interim); capsule to ODT bridging; registered quality of life outcomes; Part B safety data; and excluded populations.

Source: [Ringeisen et al. (2023)](https://www.rti.org/publication/mental-and-substance-use-disorders-prevalence-study/fulltext.pdf); [RTI International (2023)](https://www.rti.org/publication/mental-substance-use-disorders-prevalence-study-findings-report); [Generoso et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27643884/); [Maneeton et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4716733/); [FDA benzodiazepine boxed warning (2020)](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class); [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder); [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder); [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf); [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm); [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/); [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/); [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf); [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf); [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm); [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights); [Definium Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.mitrade.com/insights/news/live-news/article-8-2243334-20261110); [ICER esketamine final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf); [Mustafa et al. (2024)](https://icer.org/wp-content/uploads/2024/06/PTSD_Final-Report_For-Publication_06272024.pdf); [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
